Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 384

1.

Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 May 27;48(6):700. doi: 10.1038/ng0616-700b. No abstract available.

PMID:
27230687
2.

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 Feb;48(2):183-8. doi: 10.1038/ng.3473. Epub 2015 Dec 21. Erratum in: Nat Genet. 2016 May 27;48(6):700.

3.

Life expectancy of young adults with follicular lymphoma.

Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, Moccia A, Rancoita PM, Gribben J, Cavalli F, Gaidano G, Lister TA, Montserrat E, Ghielmini M, Zucca E.

Ann Oncol. 2015 Nov;26(11):2317-22. doi: 10.1093/annonc/mdv376. Epub 2015 Sep 11.

4.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD.

J Clin Oncol. 2015 Apr 1;33(10):1221-3. doi: 10.1200/JCO.2014.59.9373. Epub 2015 Feb 17. No abstract available.

PMID:
25691678
5.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute.

J Clin Oncol. 2014 Sep 20;32(27):3059-68.

6.

Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma - response to Meissner et al.

Greaves P, Lister TA, Gribben JG.

Br J Haematol. 2014 Aug;166(4):615-6. doi: 10.1111/bjh.12874. Epub 2014 Apr 2. No abstract available.

PMID:
24689447
7.

Treatment of Hodgkin lymphoma: a 50-year perspective.

Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT.

J Clin Oncol. 2014 Jan 20;32(3):163-8. doi: 10.1200/JCO.2013.53.1194. No abstract available.

PMID:
24441526
8.

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.

Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O'Riain C, O'Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J.

Nat Genet. 2014 Feb;46(2):176-181. doi: 10.1038/ng.2856. Epub 2013 Dec 22.

9.

Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic.

Greaves P, Sarker SJ, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A, Gribben JG, Lister TA.

Br J Haematol. 2014 Feb;164(4):526-35. doi: 10.1111/bjh.12651. Epub 2013 Nov 15.

PMID:
24236665
10.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben JG, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J.

Blood. 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.

11.

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors.

Cooke R, Jones ME, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Illidge T, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group, Swerdlow AJ.

Br J Cancer. 2013 Jun 11;108(11):2399-406. doi: 10.1038/bjc.2013.219. Epub 2013 May 7.

12.

Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.

Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG, Lister TA.

Haematologica. 2013 Apr;98(4):620-5. doi: 10.3324/haematol.2012.069583. Epub 2012 Nov 9.

13.

Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.

Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA, Calaminici M, Gribben JG.

J Clin Oncol. 2013 Jan 10;31(2):256-62. doi: 10.1200/JCO.2011.39.9881. Epub 2012 Oct 8. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1140.

14.

Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.

Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV.

J Clin Oncol. 2012 Aug 1;30(22):2745-52. doi: 10.1200/JCO.2011.38.8835. Epub 2012 Jun 25.

PMID:
22734026
15.

T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.

Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, Agrawal S, Cavenagh JD, Lister TA, Gribben JG.

Br J Haematol. 2012 Jun;157(5):580-5. doi: 10.1111/j.1365-2141.2012.09106.x. Epub 2012 Mar 26.

PMID:
22449197
16.

Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.

Quintana-Bustamante O, Lan-Lan Smith S, Griessinger E, Reyal Y, Vargaftig J, Lister TA, Fitzgibbon J, Bonnet D.

Leukemia. 2012 Jul;26(7):1537-46. doi: 10.1038/leu.2012.38. Epub 2012 Feb 10.

17.

Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis.

Greaves P, Wilson A, Matthews J, Brown DL, Auer R, Montoto S, Lister TA, Gribben JG.

Br J Haematol. 2012 Apr;157(2):201-4. doi: 10.1111/j.1365-2141.2011.08993.x. Epub 2012 Jan 9.

PMID:
22224653
18.

Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.

Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister TA, Radford JA, Rohatiner AZ, Linch DC.

J Clin Oncol. 2011 Nov 1;29(31):4096-104. doi: 10.1200/JCO.2011.34.8268. Epub 2011 Oct 3.

PMID:
21969511
19.

Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.

Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J, Oakervee H, Gribben J, Bonnet D.

Leukemia. 2012 Apr;26(4):858-60. doi: 10.1038/leu.2011.250. Epub 2011 Sep 16. No abstract available.

20.

Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.

Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A, Lister TA, Bonnet D.

Leukemia. 2011 May;25(5):770-780. doi: 10.1038/leu.2011.17. Epub 2011 Feb 22.

21.

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma.

Wrench D, Leighton P, Skibola CF, Conde L, Cazier JB, Matthews J, Iqbal S, Carlotti E, Bödör C, Montoto S, Calaminici M, Gribben JG, Lister TA, Fitzgibbon J.

Blood. 2011 Mar 17;117(11):3147-50. doi: 10.1182/blood-2010-10-315382. Epub 2011 Jan 13.

22.

AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.

Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD.

Cancer Res. 2010 May 15;70(10):3985-95. doi: 10.1158/0008-5472.CAN-09-3604. Epub 2010 May 11.

23.

Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment.

Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, Kelly G, Macdougall F, Lister TA, Gribben JG.

Blood. 2010 Jun 17;115(24):5053-6. doi: 10.1182/blood-2009-11-253260. Epub 2010 Apr 7.

24.

Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management.

Gerlinger M, Rohatiner AZ, Matthews J, Davies A, Lister TA, Montoto S.

Haematologica. 2010 Jul;95(7):1130-5. doi: 10.3324/haematol.2009.020115. Epub 2010 Jan 27.

25.

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D.

Blood. 2010 Mar 11;115(10):1976-84. doi: 10.1182/blood-2009-02-206565. Epub 2010 Jan 6.

26.

A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.

Dancey G, Violet J, Malaroda A, Green AJ, Sharma SK, Francis R, Othman S, Parker S, Buscombe J, Griffin N, Chan PS, Malhotra A, Woodward N, Ramsay A, Ross P, Lister TA, Amlot P, Begent R, McNamara C.

Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.

27.

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM, Calaminici M, Gribben JG.

Blood. 2009 Nov 19;114(21):4713-20. doi: 10.1182/blood-2009-04-217687. Epub 2009 Sep 28.

28.

An orbital period of 0.94 days for the hot-Jupiter planet WASP-18b.

Hellier C, Anderson DR, Cameron AC, Gillon M, Hebb L, Maxted PF, Queloz D, Smalley B, Triaud AH, West RG, Wilson DM, Bentley SJ, Enoch B, Horne K, Irwin J, Lister TA, Mayor M, Parley N, Pepe F, Pollacco DL, Segransan D, Udry S, Wheatley PJ.

Nature. 2009 Aug 27;460(7259):1098-100. doi: 10.1038/nature08245.

29.

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.

Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, Lee AM, Lister TA, Gribben JG.

Blood. 2009 Oct 29;114(18):3909-16. doi: 10.1182/blood-2009-02-206946. Epub 2009 Aug 26.

30.

Array-based DNA methylation profiling in follicular lymphoma.

O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM, Lister TA, Fitzgibbon J.

Leukemia. 2009 Oct;23(10):1858-66. doi: 10.1038/leu.2009.114. Epub 2009 Jul 9.

31.

Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens.

Le Dieu R, Taussig D, Lister TA, Gribben JG.

J Immunol Methods. 2009 Aug 31;348(1-2):95-100. doi: 10.1016/j.jim.2009.06.010. Epub 2009 Jul 1.

PMID:
19576900
32.

Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone.

Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, Hart J, Lai R, Montoto S, Gribben JG, Lister TA, Fitzgibbon J.

Blood. 2009 Apr 9;113(15):3553-7. doi: 10.1182/blood-2008-08-174839. Epub 2009 Feb 6.

PMID:
19202129
33.

Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation.

O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J, Rosenwald A, Ott G, Rimsza LM, Holte H, Cazier JB, Johnson NA, Campo E, Chan WC, Gascoyne RD, Young BD, Staudt LM, Lister TA, Fitzgibbon J.

Blood. 2009 Mar 5;113(10):2298-301. doi: 10.1182/blood-2008-08-174953. Epub 2009 Jan 13.

34.

BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations.

Masir N, Campbell LJ, Goff LK, Jones M, Marafioti T, Cordell J, Clear AJ, Lister TA, Mason DY, Lee AM.

Br J Haematol. 2009 Mar;144(5):716-25. doi: 10.1111/j.1365-2141.2008.07528.x. Epub 2008 Dec 11.

PMID:
19120369
35.

Stromal gene signatures in large-B-cell lymphomas.

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.

N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.

36.

Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.

Wrench D, Waters R, Carlotti E, Iqbal S, Matthews J, Calaminici M, Gribben J, Lister TA, Fitzgibbon J.

Haematologica. 2009 Jan;94(1):148-50. doi: 10.3324/haematol.13533. Epub 2008 Nov 23. No abstract available.

37.

Treatment of Stage IIIa Hodgkin's disease: long follow-up perspective.

Lister TA.

J Clin Oncol. 2008 Nov 10;26(32):5144-6. doi: 10.1200/JCO.2008.19.0330. Epub 2008 Oct 14. No abstract available.

PMID:
18854554
38.

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.

Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon MC, Sinclair GD, Leber B, Johnson PR, Macheta A, Yin JA, Barnett MJ, Lister TA, Fitzgibbon J.

Blood. 2008 Dec 1;112(12):4639-45. doi: 10.1182/blood-2008-05-156745. Epub 2008 Aug 21.

PMID:
18723428
39.

The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.

O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J.

Blood. 2008 Oct 15;112(8):3126-9. doi: 10.1182/blood-2008-05-154013. Epub 2008 Jul 15.

40.

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.

Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister TA, Fitzgibbon J.

J Clin Oncol. 2008 Nov 20;26(33):5429-35. doi: 10.1200/JCO.2008.16.0333. Epub 2008 Jun 30.

PMID:
18591546
41.

Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D.

Blood. 2008 Aug 1;112(3):568-75. doi: 10.1182/blood-2007-10-118331. Epub 2008 Jun 3.

PMID:
18523148
42.

Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia.

Raghavan M, Smith LL, Lillington DM, Chaplin T, Kakkas I, Molloy G, Chelala C, Cazier JB, Cavenagh JD, Fitzgibbon J, Lister TA, Young BD.

Blood. 2008 Aug 1;112(3):814-21. doi: 10.1182/blood-2008-01-132431. Epub 2008 May 19.

PMID:
18490517
43.

WTX is rarely mutated in acute myeloid leukemia.

Owen C, Virappane P, Alikian M, Stasevich I, Summers K, Lillington D, Bonnet D, Burnett A, Mills K, Lister TA, Fitzgibbon J.

Haematologica. 2008 Jun;93(6):947-8. doi: 10.3324/haematol.12509. Epub 2008 May 6. No abstract available.

44.

Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.

Paulsson K, Cazier JB, Macdougall F, Stevens J, Stasevich I, Vrcelj N, Chaplin T, Lillington DM, Lister TA, Young BD.

Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13. doi: 10.1073/pnas.0800408105. Epub 2008 May 5.

45.
46.

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study.

Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister TA, Goldstone AH; EBMT Lymphoma Working Party.

Leukemia. 2007 Nov;21(11):2324-31. Epub 2007 Jul 19.

PMID:
17637813
47.

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.

Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS.

J Clin Oncol. 2007 Jun 20;25(18):2554-9. Epub 2007 May 21.

PMID:
17515573
48.

Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma.

Fitzgibbon J, Iqbal S, Davies A, O'shea D, Carlotti E, Chaplin T, Matthews J, Raghavan M, Norton A, Lister TA, Young BD.

Leukemia. 2007 Jul;21(7):1514-20. Epub 2007 May 10.

PMID:
17495976
49.

Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.

Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZ, Lister TA.

J Clin Oncol. 2007 Jun 10;25(17):2426-33. Epub 2007 May 7.

PMID:
17485708
50.

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.

Supplemental Content

Loading ...
Support Center